- Home
- LSF vs IGC Comparison
LSF vs IGC Comparison
Compare LSF & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | IGC |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3M | 31.5M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | LSF | IGC |
|---|---|---|
| Price | $3.11 | $0.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $5.25 |
| AVG Volume (30 Days) | 35.5K | ★ 1.0M |
| Earning Date | 05-06-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,889,286.00 | $1,271,000.00 |
| Revenue This Year | $90.82 | N/A |
| Revenue Next Year | N/A | $13.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 15.23 | N/A |
| 52 Week Low | $1.96 | $0.24 |
| 52 Week High | $7.94 | $0.50 |
Technical Indicators
Market Signals| Indicator | LSF | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 64.13 | 50.19 |
| Support Level | $2.41 | $0.28 |
| Resistance Level | $3.60 | $0.31 |
| Average True Range (ATR) | 0.23 | 0.02 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 78.85 | 22.22 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.